Clinical trials: Circulating Tumor DNA
- Condition Circulating Tumor DNA
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Neoplasms, Cancer
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early.
- Trial name
- NCT03085888
- Where
- 35 sites in United States
- Volunteers
- 99,481 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Cancer
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers.
- Trial name
- NHS-Galleri (NCT05611632)
- Testing
- Multi-cancer early detection test (Galleri test)
- Where
- United Kingdom
- Volunteers
- 142,318 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Colon Cancer, Colon Adenomas
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream.
- Conditions
- Colon Cancer, Colon Adenomas, Colon Polyps
- Trial name
- NCT02665299
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Pathway Genomics
Cancer, Early Detection of Cancer
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
- Conditions
- Cancer, Early Detection of Cancer, Circulating Cell-free DNA
- Trial name
- PREVENT (NCT05227534)
- Testing
- OverC multi-cancer detection blood test
- Where
- China
- Volunteers
- 12,500 people, healthy volunteers welcome
- Sponsor
- Guangzhou Burning Rock Dx Co., Ltd.
Cancer
Galleri® in the Medicare Population.
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test.
- Trial name
- NCT05673018
- Testing
- Multi-Cancer Early Detection Test (Galleri®)
- Where
- 72 sites in United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Breast Cancer, Breast Cancer Female
Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
A central challenge in the fight against breast cancer is how to detect disease in a noninvasive manner before it is detectable by imaging methods.
- Trial name
- NCT03480659
- Where
- Kazakhstan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- HKGepitherapeutics
Colorectal Cancer (CRC), Advanced Adenomas (AA)
Collection of Samples USOPTIVAL Study
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC…
- Trial name
- NCT04792684
- Testing
- Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
- Where
- 16 sites in United States
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Universal Diagnostics
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Gastric Cancer
Early Detection and Post-operative Monitoring of Gastric Cancer
This study is to determine the performance of non-invasive new multi-target biomarkers in the early detection and post-operative monitoring of gastric cancer.
- Trial name
- NCT06232395
- Testing
- DNA test
- Where
- 2 sites in China
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Suzhou Huhu Health & Technology Inc.
Colorectal Cancer
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance
This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who…
- Trial name
- PROVE (NCT07310446)
- Where
- United States
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Universal Diagnostics
Early Detection of Cancer, Cancer
REFLECTION: A Clinical Practice Learning Program for Galleri®
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in…
- Trial name
- NCT05205967
- Testing
- MCED, SOC
- Where
- 16 sites in United States
- Volunteers
- 14,633 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Mutation, Neoplasms
Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease
Pathway Genomics Corporation (Pathway Genomics), a San Diego, California company, is involved in the development and validation of new molecular diagnostic assays for the analysis of circulating tumor deoxyribonucleic acid (DNA)…
- Trial name
- H1000 (NCT02612350)
- Testing
- ctDNA Analysis for the Detection of Genetic Mutations
- Where
- United States
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- Pathway Genomics
Pulmonary Nodules
Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules
AnchorDx is using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS) to develop a blood-based assay for differentiating benign and malignant pulmonary nodules early.
- Trial name
- NCT03651986
- Testing
- ctDNA methylation analysis by NGS
- Where
- 23 sites in China
- Volunteers
- 10,560 people, healthy volunteers welcome
- Sponsor
- AnchorDx Medical Co., Ltd.
Colorectal Cancer Screening
Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
The purpose of this study is to collect clinical specimens from subjects with a diagnosis of colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study eligibility criteria.
- Trial name
- NCT05127096
- Testing
- FirstSight blood test
- Where
- 15 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CellMax Life
Colorectal Cancer
Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection
The DNA methylation targets in preoperative plasma samples of the subjects will be detected by the multi-gene methylation test (ColonAiQ), and the test accuracy will be evaluated by compared with the clinical diagnosis evidence.
- Trial name
- NCT06347887
- Testing
- ColonAiQ test and Colonoscopy
- Where
- 7 sites in China
- Volunteers
- 1,965 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Lung Cancer, Lung Cancer, Nonsmall Cell
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods.
- Conditions
- Lung Cancer, Lung Cancer, Nonsmall Cell, Lung Cancer, Small Cell
- Trial name
- NCT03499678
- Where
- Kazakhstan
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- HKGepitherapeutics